Biosimilars should be considered by doctors to be interchangeable with their original biologic brands and should be able to be substituted by pharmacists, under certain conditions, French off-patent industry association Gemme has declared in a position statement.
French Body Favors Pharmacy Substitution For Biosimilars
But Move Is Not Supported By Wider European Off-Patent Industry
French off-patent association Gemme has made a bold show of support for pharmacy-level biosimilar substitution in a position statement published by the industry body. However, the proposals run against the views of broader European industry association Medicines for Europe and come against the backdrop of recently-adopted French legislation that ensures doctors will be involved in biologic substitution.
